Beroni Group Published an Article Related to Single-Domain Antibodies in the FEBS Journal

NEW YORK and SYDNEY, Australia, Oct. 28, 2021 (GLOBE NEWSWIRE) — Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based biopharmaceutical enterprise, today announced that its article entitled “Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies” has been accepted for publication and undergone full review in the FEBS Journal. The full article can be viewed at https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/febs.16239.

The FEBS Journal is an international peer-reviewed non-profit society journal devoted to publishing high-quality papers reporting significant advances in the molecular life sciences.

The published article is related to the scientific findings derived from Beroni’s current research of the development of a medical solution using single-domain antibodies (sdAbs) for the SARS-CoV-2 coronavirus. The Company has identified 2 crystal structures of nucleocapsid protein C-terminal domain. Nucleocapsid protein is a major structural protein of SARS-CoV-2 and plays an important role in viral RNA packing, replication, assembly, and infection. Through screening a sdAbs library, the scientific team has identified four sdAbs targeting different regions of nucleocapsid protein with high affinities that have future potential to be used in viral detection and therapeutic purposes.

“We are delighted to progress further in our coronavirus research program and to publish our new findings in the FEBS journal. The Company plans to carry out a series of experiments to gradually transform the results into clinical trials and find a new way for the diagnosis and treatment of the new coronavirus. Beroni hopes our efforts can contribute to the basic understanding of the SARS-CoV-2 coronavirus and the global development of antiviral drugs.” said Jacky Zhang, Chairman and CEO of Beroni Group.

About Beroni Group Limited

Beroni Group is an Australia-based biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

Forward-Looking Statements Disclaimer
This press release contains forward-looking statements or forward-looking information, within the meaning of applicable United States and Australian securities laws with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “intend”, “believe”, “potential” and similar expressions.

Forward-looking information contained in this press release is based on Company management’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward-looking statements involve significant risks, uncertainties and assumptions, and there can be no assurance that such statements, or its underlying risks, uncertainties and assumptions will prove to be accurate. Factors that could cause actual results or events to differ materially include, without limitation, risks related to laws, rules and regulation applicable to the Company as well as the industry in which it operates (including in respect of taxes and other levies), economic or market conditions on both a national and global level, currency fluctuations, risks inherent to other entities at a similar stage of development and industry in which the Company currently is, competition from the Company’s competitors, unsatisfactory development or marketing of the Company and/or its products or services, regulatory action or litigation (including product liability claims), and failure to enter into agreements or arrangements with other parties on fair or reasonable terms. Forward-looking information is made only as of the date on which it is provided and, except as may be required by applicable laws, the Company disclaims any intent or obligation to update such forward-looking information whether as a result of new information, future events or otherwise.

For more information, please contact our IR consultants at:

Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com